{"page_content": "6      KODIAK 2021 ESG REPORT BACK TO CONTENTS >>\nAbout Kodiak \nWHO WE ARE\nFounded in 2009, Kodiak is a clinical stage biopharmaceutical company committed \nto researching, developing and commercializing transformative therapeutics  \nto treat high-prevalence retinal diseases. Our goal is to design and manufacture \nnext-generation retinal medicines to prevent and treat the leading causes of \nblindness globally.\nBased in Palo Alto, California, Kodiak has assembled a team comprising  \nthose we believe are leading practitioners in the fields of biomedical research  \nand pharmaceutical manufacturing to realize our goals.\nMONOSPECIFIC BI-SPECIFIC TRIPLET \nTo achieve our long-term objectives, we are advancing a robust \npipeline of medicines built on our innovative ABC Platform.\n", "metadata": {"source": "NASDAQ_KOD_2021.pdf", "page": 5, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}